Amundi Asset Management US’s Juno Therapeutics, Inc. JUNO Stock Holding History

Amundi Asset Management US’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-137,300	Closed	-$6.28M	–	1634
2017 Q4	$6.28M	Buy	+137,300	New	+$6.85M	0.01%	785

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Amundi Asset Management US's JUNO Position: Q1 2018 in Review

Amundi Asset Management US sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 137,300 shares — an estimated $6.28M sold.

Amundi Asset Management US first reported a position in JUNO in Q4 2017 and held it in 1 quarter. The position peaked at $6.28M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Amundi Asset Management US reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Amundi Asset Management US sold 137,300 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $6.28M.
Amundi Asset Management US first reported a position in Juno Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
Amundi Asset Management US's Juno Therapeutics, Inc. position peaked at $6.28M in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Amundi Asset Management US's 13F filing for Q1 2018, filed 15 May 2018.